CPTAC Proteomics
CPTAC proteomics is a pivotal approach in cancer research, enabling large-scale proteomic analyses to systematically investigate cancer-associated protein expression, post-translational modifications (PTMs), and interaction networks. Cancer is a highly heterogeneous disease governed by intricate regulatory layers, including genetic mutations, epigenetic modifications, and protein dysfunction. While traditional cancer genomics studies, such as those from The Cancer Genome Atlas (TCGA), have revealed key mutations and gene expression changes, genomic alterations alone cannot fully explain cancer cell behavior. Many oncogenic mutations do not directly affect gene expression but instead influence protein translation, degradation, or post-translational modifications. To bridge this gap, the CPTAC proteomics initiative provides comprehensive protein-level insights, facilitating a deeper understanding of cancer biology and identifying reliable molecular targets for precision medicine.
A fundamental advantage of CPTAC proteomics is its ability to reveal protein-level information that genomics alone cannot provide. Unlike genetic mutations or transcriptomic alterations, protein expression and modification states offer a more direct representation of cancer phenotypes. Furthermore, proteomic technologies enable the identification of functional changes in cancer cells. For example, PTM profiling can uncover cancer-specific signaling disruptions, potentially leading to novel therapeutic strategies.
However, CPTAC proteomics also presents challenges. The inherent heterogeneity of cancer tissues results in substantial inter-patient variability in proteomic profiles, complicating data analysis and interpretation. Additionally, the complexity of proteomic workflows-including sample preparation, mass spectrometry acquisition, and computational analysis-necessitates stringent quality control at every stage. Moreover, the dynamic nature of proteins and their subcellular localization adds further complexity, often requiring the integration of multi-omics data to enhance research accuracy and biological relevance.
Methodologies in CPTAC Proteomics
1. Quantitative Proteomics
Quantitative proteomics is a core methodology in CPTAC proteomics, facilitating the measurement of differential protein expression between cancerous and normal tissues. Researchers employ labeling techniques (e.g., SILAC, TMT, iTRAQ) or label-free approaches (e.g., DIA, SWATH-MS) to conduct high-throughput protein abundance analyses. Since protein expression levels provide a more direct representation of cancer cell behavior than transcriptomic changes, quantitative proteomics is indispensable for cancer research.
2. Post-Translational Modification (PTM) Proteomics
Aberrant signaling in cancer cells is often driven by dysregulated PTMs, such as phosphorylation, acetylation, and ubiquitination. CPTAC proteomics emphasizes phosphorylation analysis, as aberrant kinase activity is a hallmark of dysregulated cancer pathways. By integrating phosphopeptide enrichment with mass spectrometry, researchers can identify dysregulated phosphorylation sites, elucidate tumor signaling mechanisms, and discover novel therapeutic targets.
3. Interactome Proteomics
Cancer progression is orchestrated by complex protein interaction networks rather than isolated genetic alterations. CPTAC proteomics employs affinity purification-mass spectrometry (AP-MS) to systematically map cancer-related protein interactions, uncover novel oncogenic drivers, and elucidate their roles in signaling, metabolism, and cell cycle regulation.
MtoZ Biolabs provides high-precision proteomics services, leveraging cutting-edge methodologies to facilitate cancer biomarker discovery and therapeutic target identification.
MtoZ Biolabs, an integrated chromatography and mass spectrometry (MS) services provider.
Related Services
How to order?
